MAPT and Alzheimer disease: In the Phase 2 double-blinded, randomized placebo-controlled trial (RCT) TRAILBLAZER-ALZ (ClinicalTrials.gov identifier: NCT03367403), 257 patients with MCI/mild dementia due to AD, positive amyloid PET and low-medium tau burden on tau PET were randomized to receive monthly intravenous infusions of donanemab or placebo for 76 weeks [2].